Stock AnalizPulse Biosciences, Inc. PLSE
Medical/Dental Instruments · IPO 2016 · data as of November 13, 2026
Pulse Biosciences, Inc. (PLSE) is a healthcare company listed in the US with a market value of about $3.7B. In the twelve months to September 30, 2026 it had revenue of $1M and net income of -$84M, a net margin of -5603.9%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -85%.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $350000 | $0 | $0 | $700000 | $1M | $0 | — | — | — | — |
| Net income | -$84M | -$73M | -$54M | -$42M | -$59M | -$64M | -$50M | -$47M | -$38M | -$26M | -$10M |
| Free cash flow | -$64M | -$54M | -$36M | -$33M | -$47M | -$55M | -$36M | -$35M | -$24M | -$14M | -$8M |
| EPS (diluted) | $-1.21 | $-1.08 | $-0.92 | $-0.85 | $-1.72 | $-2.28 | $-2.14 | $-2.26 | $-2.20 | $-1.73 | $-0.86 |
| Net margin | -5603.9% | -20794.6% | — | — | -8357.9% | -4489.4% | — | — | — | — | — |
| ROIC | — | -87.2% | -45.5% | -81.4% | -78.8% | -134.2% | -145.9% | -101.1% | -44.7% | -43.9% | -29.7% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $67.67, 34% above the current price; targets range from $60.00 to $74.00; the consensus rating is “Strong buy”; expected EPS is $-1.05 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Pulse Biosciences pay a dividend?
Not currently.
Is Pulse Biosciences a good stock to buy?
We do not give buy or sell advice. Pulse Biosciences scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.